<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urovest</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник урологии</journal-title><trans-title-group xml:lang="en"><trans-title>Urology Herald</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2308-6424</issn><publisher><publisher-name>Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2308-6424-2018-6-2-4-12</article-id><article-id custom-type="elpub" pub-id-type="custom">urovest-200</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>КОРРЕКЦИЯ НАРУШЕНИЙ ФУНКЦИИ ЭНДОТЕЛИЯ В ПОЧКЕ ДИСТАНТНЫМ ИШЕМИЧЕСКИМ И ФАРМАКОЛОГИЧЕСКИМ ПРЕКОНДИЦИОНИРОВАНИЕМ ПРИ ТЕПЛОВОЙ ИШЕМИИ</article-title><trans-title-group xml:lang="en"><trans-title>THE CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH THE HELP OF DISTANT ISCHEMIC AND PHARMACOLOGICAL PRECONDITIONING WITH THERMAL LOCAL ASPHYXIA OF KIDNEY</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0906-9851</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Братчиков</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Bratchikov</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Братчиков Олег Иванович – д.м.н., профессор, заведующий, кафедра урологии </p></bio><bio xml:lang="en"/><email xlink:type="simple">bratov45@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Покровский</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pokrovskiy</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Покровский Михаил Владимирович – д.м.н., профессор, заведующий, кафедра фармакологии и клинической фармакологии</p><p>директор </p></bio><bio xml:lang="en"><p>Mikhail V. Pokrovskiy – MD, PhD (M), DMS, Full Professor, Head </p><p>Department of Pharmacology and Clinical Pharmacology</p><p>Director</p></bio><email xlink:type="simple">pokrovskii@bsu.edu.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6403-6131</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елагин</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Elagin</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елагин Владислав Викторович – ассистент, кафедра урологии  </p><p>тел.: +7 (919) 219-02-85</p></bio><bio xml:lang="en"><p>Vladislav V. Elagin – MD, Assistant of the Department of Urology</p><p>tel.: +7 (919) 219-02-85</p></bio><email xlink:type="simple">vlad.elagin2014@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4505-3988</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Костина</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostina</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Костина Дарья Александровна – ассистент, кафедра фармакологии и клинической фармакологии </p></bio><bio xml:lang="en"><p>Darya A. Kostina – MD, Assistant </p><p>Department of Pharmacology and Clinical Pharmacology</p></bio><email xlink:type="simple">kostina_da@bsu.edu.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Курский государственный медицинский университет» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kursk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГАОУ ВО «Белгородский государственный национальный исследовательский университет» Минобрнауки РФ, Медицинский институт</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Belgorod National Research University, Medical Institute; Research Institute of Living System`s Pharmacology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО «Белгородский государственный национальный исследовательский университет» Минобрнауки РФ, Медицинский институт</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Belgorod National Research University, Medical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>14</day><month>07</month><year>2018</year></pub-date><volume>6</volume><issue>2</issue><fpage>4</fpage><lpage>12</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Братчиков О.И., Покровский М.В., Елагин В.В., Костина Д.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Братчиков О.И., Покровский М.В., Елагин В.В., Костина Д.А.</copyright-holder><copyright-holder xml:lang="en">Bratchikov O.I., Pokrovskiy M.V., Elagin V.V., Kostina D.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.urovest.ru/jour/article/view/200">https://www.urovest.ru/jour/article/view/200</self-uri><abstract><p>В работе представлены результаты исследования нарушений функции эндотелия, возникающих при моделировании «тепловой ишемии» почки и возможности их коррекции дистантным ишемическими и фармакологическим прекондиционированием. Моделирование «тепловой ишемии» почки характеризуется нарушением микроциркуляции и экспрессией eNOS в ткани почек. Применение дистантного ишемического прекондиционирования и ингибиторов фосфодиэстеразы 5 типа силденафила и тадалафила приводит к выраженной коррекции нарушений микроциркуляции и активности eNOS. При моделировании «тепловой ишемии» почки на фоне дисфункции эндотелия вызванной ADMA-подобным L-NAME индуцированным дефицитом оксида азота наблюдаются более выраженные нарушения микроциркуляции и активности eNOS. Применение дистантного ишемического и фармакологического прекондиционирования ингибиторами фосфодиэстеразы 5 типа при данном типе патологии приводило к выраженной коррекции нарушений микроциркуляции и активности eNOS. Введение блокатора АТФ-зависимых К+ каналов глибенкламида при коррекции дистантным ишемическим и фармакологическим прекондиционированием нарушений, вызванных моделированием «тепловой ишемии» почки, приводит к снижению их эффективности.</p><p>Раскрытие информации: Исследование не имело спонсорской поддержки. Авторы заявляют об отсутствии конфликта интересов.</p></abstract><trans-abstract xml:lang="en"><p>This article contains the results of research of the endothelial dysfunction arising during the modeling of thermal local asphyxia of kidney and possibilities of their correction by distant ischemic and pharmacological preconditioning. The modeling of thermal local asphyxia of kidney is characterized by the disturbance of microcirculation and expression of eNOS in the kidney tissue. The usage of distant ischemic preconditioning and phosphodiesterase inhibitors type 5 sildenafil and tadalafil leads to pronounced correction of microcirculation dysfunction and activity of eNOS. During the modeling of thermal local asphyxia of kidney against endothelium dysfunction caused by ADMA-like L-NAME induced deficiency of nitric oxide more pronounced dysfunction of microcirculation and activity of eNOS are observed. The usage of distant ischemic and pharmacological preconditioning with the help of phosphodiesterase inhibitors type 5 in this type of pathology led to pronounced correction of microcirculation dysfunction and activity of eNOS. The injection of glibenclamide blocker of ATP – dependent K+ channels during the correction of the disturbance caused by the modeling of thermal local asphyxia of kidney with the help of distant ischemic and pharmacological preconditioning leads to the decrease of its efficiency.</p><p>Disclosure: The study did not have sponsorship. The authors have declared no conflicts of interest.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тепловая ишемия</kwd><kwd>микроциркуляция почки</kwd><kwd>прекондиционирование</kwd><kwd>реперфузия</kwd><kwd>ингибиторы фосфодиэстеразы 5 типа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>thermal local asphyxia</kwd><kwd>microcirculation of kidney</kwd><kwd>preconditioning</kwd><kwd>reperfusion</kwd><kwd>phosphodiesterase inhibitors type 5</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Лихванцев В.В., Мороз В.В., Гребенчиков О.А., Гороховатский Ю.И., Заржецкий Ю.В., Тимошин С.С., Левиков Д.И., Шайбакова В.Л. Ишемическое и фармакологическое прекондиционирование. Общая реаниматология. 2011;7(6):59. DOI: 10.15360/1813-9779-2011-6-59</mixed-citation><mixed-citation xml:lang="en">Likhvantsev VV, Moroz VV, Grebenchikov OA, Gorokhovatsky YI, Zarzhetsky YV, Timoshin SS, Levikov DI, Shaibakova VL. Ischemic and Pharmacological Preconditioning. General Reanimatology. 2011;7(6):59. (In Russ.) DOI: 10.15360/1813-9779-2011-6-59</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Маслов Л.Н. Новые подходы к профилактике и терапии ишемических и реперфузионных повреждений сердца при остром инфаркте миокарда. Сибирский медицинский журнал. 2010;25(2-1):17–24.</mixed-citation><mixed-citation xml:lang="en">Maslov LN. New approaches to prophylaxis and therapy of ischemic and reperfusion damages of the heart at acute myocardial infarction. Sibirskiyi medicinskiyi jurnal. 2010;25(2-1):17–24. (in Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine receptor to KATP. Annual Review of Physiology. 2000;62:79-109. DOI: 10.1146/annurev.physiol.62.1.79</mixed-citation><mixed-citation xml:lang="en">Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine receptor to KATP. Annual Review of Physiology. 2000;62:79-109. DOI: 10.1146/ annurev.physiol.62.1.79</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2005;288(2):H971-6. DOI: 10.1152/ajpheart.00374.2004</mixed-citation><mixed-citation xml:lang="en">Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2005;288(2):H971-6. DOI: 10.1152/ajpheart.00374.2004</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Inserte J, Barrabés JA, Hernando V, Garcia-Dorado D. Orphan targets for reperfusion injury. Cardiovasc Res. 2009;83(2):169-78. DOI: 10.1093/cvr/cvp109</mixed-citation><mixed-citation xml:lang="en">Inserte J, Barrabés JA, Hernando V, Garcia-Dorado D. Orphan targets for reperfusion injury. Cardiovasc Res. 2009;83(2):169-78. DOI: 10.1093/cvr/cvp109</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Perrelli MG, Pagliaro P, Penna C. Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. World J Cardiol. 2011;3(6):186-200. DOI: 10.4330/wjc.v3.i6.186</mixed-citation><mixed-citation xml:lang="en">Perrelli MG, Pagliaro P, Penna C. Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. World J Cardiol. 2011;3(6):186-200. DOI: 10.4330/wjc.v3.i6.186</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz-Meana M, García-Dorado D. Pathophysiology of ischemia-reperfusion injury: new therapeutic options for acute myocardial infarction. Revista Española de Cardiología. 2009;62(2):199–209. DOI: 10.1016/S1885-5857(09)71538-5</mixed-citation><mixed-citation xml:lang="en">Ruiz-Meana M, García-Dorado D. Pathophysiology of ischemia-reperfusion injury: new therapeutic options for acute myocardial infarction. Revista Española de Cardiología. 2009;62(2):199–209. DOI: 10.1016/S1885- 5857(09)71538-5</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ragulina VA, Kostina DA, Dovgan AP, Burda YE, Nadezhdin SV. Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology. Research result: pharmacology and clinical pharmacology. 2017;3(1):114-124. DOI: 10.18413/2500-235X-2017-3-1-114-124</mixed-citation><mixed-citation xml:lang="en">Ragulina VA, Kostina DA, Dovgan AP, Burda YE, Nadezhdin SV. Nuclear factor kappa B as a potential target for pharmacological correction endothelium-associated pathology. Research result: pharmacology and clinical pharmacology. 2017;3(1):114-124. DOI: 10.18413/2500- 235X-2017-3-1-114-124</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Danilenko LM, Klochkova GN, Kizilova IV, Korokin MV. Pharmacological preconditioning by recombinant erythropoietin as the possibility of increasing the stability of tissue of the retina to reperfusion ischemia in experiment. Research result: pharmacology and clinical pharmacology. 2016;2(3):95-100. DOI: 10.18413/2500-235X-2016-2-3-95-100</mixed-citation><mixed-citation xml:lang="en">Danilenko LM, Klochkova GN, Kizilova IV, Korokin MV. Pharmacological precondiƟ oning by recombinant erythropoieƟ n as the possibility of increasing the stability of tissue of the retina to reperfusion ischemia in experiment. Research result: pharmacology and clinical pharmacology. 2016;2(3):95-100. DOI: 10.18413/2500-235X - 2016-2-3-95-100</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
